Manufacture with AI! Leumas Secures Fresh Funds to Reinvent How Products Are Made

In an era where speed, precision, and flexibility define the success of modern manufacturing, one deeptech startup is quietly rewriting the playbook. Meet Leumas, a startup that’s not just building factories — it’s reimagining how factories are built, scaled, and operated.

The Bengaluru-based company has just raised $2.2 million in a seed round led by Capital 2B, a deeptech-focused fund backed by Info Edge and Temasek. The round also saw participation from Capital-A and Anicut Capital, further cementing investor confidence in the company’s potential to disrupt traditional manufacturing in pharma and wellness sectors.

But what exactly is Leumas doing that’s caught the attention of some of the most respected names in venture capital?

From Traditional to Transformational: The Leumas Edge

Founded in 2016 by Subhajit Biswas and Nitesh K, Leumas offers something rare in Indian deeptech — an end-to-end on-demand manufacturing platform for wellness and pharma brands. Think “Factory-as-a-Service” — a term often tossed around in tech circles, but rarely seen executed at scale in real-world, physical product industries.

At the heart of Leumas’ offering is its cyber-physical manufacturing technology — modular, software-defined production lines embedded with AI-led robotics, vision-based quality systems, and autonomous operations. This makes their production units not only smart but capable of adapting rapidly to changing product needs and compliance requirements.

In simple terms, Leumas isn’t just making factories smarter — it’s making them modular, scalable, and intelligent enough to function like apps on a phone: plug-and-play, fast to deploy, and tailored for specific brand requirements.

Why This Matters: A Market Ready for Change

The pharma and wellness industry, especially post-COVID, is witnessing rapid digitisation and demand for faster go-to-market cycles. Traditional factories are often too rigid and capital-intensive for new-age brands that want agility, speed, and global scalability.

According to industry research, the outsourced development and manufacturing (CDMO) market in pharma and wellness is projected to cross $400 billion by 2030. Startups like Leumas, with their automation-led, modular approach, are perfectly positioned to ride this wave of transformation.

This isn't just a bet on automation — it's a bet on redefining how brands launch and scale physical products in the wellness and pharmaceutical space.

Where the Money’s Going: Scaling the Vision

The freshly raised funds will be used to scale Leumas’ R&D capabilities, expand its modular manufacturing infrastructure, and roll out pilot deployments of dedicated factories tailored for wellness and pharma brands.

These aren’t just experiments — Leumas is already working with some of the top wellness brands and claims to have co-developed over 120 products across India, the US, and the MENA region using its technology.

Moreover, it has signed partnerships with major pharma and food research institutions to set up factory units powered by its modular systems — an indication that this startup isn’t just playing in the startup sandbox anymore. It’s stepping into the big league.

Both founders — Subhajit Biswas and Nitesh K — come from deep operational and tech backgrounds. Their mission is bold yet precise: “Factories should be as flexible as software, and as intelligent as the products they make.”

With Leumas, they’ve fused R&D, automation, and software intelligence to offer a solution that not only produces better outcomes but also allows brands to scale without the traditional risks and delays associated with brick-and-mortar manufacturing.

India’s Deeptech Moment?

While India has long been a global hub for software services, deeptech manufacturing startups like Leumas are opening new frontiers. As the country continues to build an ecosystem of AI, robotics, and advanced engineering, Leumas is a shining example of what Indian innovation can deliver — not just for domestic needs, but for global markets.

With early traction, visionary tech, and a clear value proposition, Leumas’ journey is just beginning — and the $2.2 million seed round may well be the ignition point for something much larger.